Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Myelogenous Leukemia, Acute, Childhood: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Myelogenous Leukemia, Acute, Childhood: 1 US clinical trial tracked, none currently recruiting.

Myelogenous Leukemia, Acute, Childhood is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Therapeutic Advances in Childhood Leukemia Consortium, running 1 of these trials.

Enrollment posture brief

Registry condition myelogenous-leukemia-acute-childhood

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Myelogenous Leukemia, Ac (th…0%
Open-enrollment share among volume-matched conditions near Myelogenous Leukemia, Acute, Childhood

Myelogenous Leukemia, Acute, Childhood has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Myelogenous Leukemia, Acute, Childhood on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Myelogenous Leukemia, Acute, Childhood is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Myelogenous Leukemia, Acute, Childhood records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Intrathecal Methotrexate (IT MTX) Drug
1 trials
Intrathecal (IT) Cytarabine Drug
1 trials
Azacytidine Drug
1 trials
Cytarabine Drug
1 trials
Fludarabine Drug
1 trials

US sites by state

Facility locations filed on Myelogenous Leukemia, Acute, Childhood trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Washington 1 trials
Utah 1 trials
Texas 1 trials
Tennessee 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Myelogenous Leukemia, Acute, Childhood page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelogenous Leukemia, Acute, Childhood condition card totals 1 registered trials; most-linked intervention Intrathecal Methotrexate (IT MTX); top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.